As Advair struggles, GlaxoSmithKline seeks expanded label for blockbuster-to-be Trelegy

27th November 2017 Uncategorised 0

Facing the prospect of near-term competition to respiratory stalwart Advair, GlaxoSmithKline is pushing to grow new drug Trelegy Ellipta by seeking an expanded indication at the FDA.

More: As Advair struggles, GlaxoSmithKline seeks expanded label for blockbuster-to-be Trelegy
Source: fierce